<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="306">
  <stage>Registered</stage>
  <submitdate>26/08/2005</submitdate>
  <approvaldate>6/09/2005</approvaldate>
  <actrnumber>ACTRN12605000316606</actrnumber>
  <trial_identification>
    <studytitle>A Phase II study of Paclitaxel, and Vinorelbine (Pacl-Vin) in Hormone-refractory metastatic prostate cancer: Double Tubulin Targeting</studytitle>
    <scientifictitle>A Phase II study of Paclitaxel and Vinorelbine (PaclVin) in Hormone-refractory metastatic prostate cancer: Double Tubulin Targeting. The outcome measured is PSA response.</scientifictitle>
    <utrn />
    <trialacronym>Pacl-vin</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Metastatic Prostate Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Prostate</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Chemotherapy is given twice every three weeks, ie. Paclitaxel 40mg/m2 IV and Vinorelbine 20mg/m2 IV. The duration of treatment: as long as the treatment is working, or the side effects are tolerable.</interventions>
    <comparator>uncontrolled</comparator>
    <control>Uncontrolled</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>PSA response</outcome>
      <timepoint>Measured at week 6 and week 10.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Overall survival</outcome>
      <timepoint>From day 1 until day of progression or death</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Progression free survival</outcome>
      <timepoint>From day 1 until day of progression or death</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Toxicity</outcome>
      <timepoint>Every 3 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Quality of life</outcome>
      <timepoint>Every 3 weeks.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Hormone-refractory prostate cancer with metastases documented by bone scan and/or CT scan, with rising PSA and/or progressive metastatic disease with serum testosterone &lt; 3.5 nmol/L. - Patients who have not had bilateral orchidectomy should continue therapy with a Luteinizing hormone-releasing hormone analogue. Antiandrogens should be ceased at least 28 days prior to study entry. - Adequate bone marrow function: absolute neutrophil count (ANC) at least 1.5 X 109/L and platelets at least 100 X 109/L. - Adequate renal function: serum creatinine less than or equal to 200µmol/L. - Adequate liver function: bilirubin less than or equal to 20µmol/L and AST/ALT less than or equal to 5 X upper limit of normal. - ECOG performance status 0-2. - Not more than one previous line of chemotherapy (prior exposure to vinorelbine and/or taxanes not allowable).</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Prior radiotherapy within 21 days - Prior radioactive strontium within 42 days. - Concurrent treatment with other investigational agents.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>5/05/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Bristol Myers Squibb</primarysponsorname>
    <primarysponsoraddress>556 Princes Highway

NOBLE PARK NORTH, VICTORIA 3174</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Barwon Health</fundingname>
      <fundingaddress>Ryrie Street Geelong</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Bristol Myers Squibb</fundingname>
      <fundingaddress>556 Princes Highway

NOBLE PARK NORTH, VICTORIA 3174</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Pierre Fabre Medicament</fundingname>
      <fundingaddress>International House, Pendlebury Road, 
Manchester</fundingaddress>
      <fundingcountry>France</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Geelong Regional Medical research foundation</fundingname>
      <fundingaddress>Ryrie street
Geelong</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Pierre Fabre Medicament</sponsorname>
      <sponsoraddress>International House, Pendlebury Road, 
Manchester</sponsoraddress>
      <sponsorcountry>France</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Barwon Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Frankston Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Sanjeev Sewak</name>
      <address>Andrew Love Cancer Centre
70 Swanston St
Geelong VIC 3220</address>
      <phone>+61 3 52267477</phone>
      <fax>+61 3 52465168</fax>
      <email>sanjeev@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Anne Woollett</name>
      <address>Andrew Love Cancer Centre
70 Swanston St
Geelong VIC 3220</address>
      <phone>+61 3 52267391</phone>
      <fax>+61 3 52465168</fax>
      <email>annewo@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Anne Woollett</name>
      <address>Andrew Love Cancer centre, 70 Swanston Street, Geelong Victoria 3220</address>
      <phone>03 5226 7391</phone>
      <fax>03 52 46 5168</fax>
      <email>annewo@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>